Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN.

J Clin Oncol. 2005 Dec 20;23(36):9312-8.

PMID:
16361630
2.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
3.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
4.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
5.

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V.

Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Review.

PMID:
19398943
6.

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

Brauch H, Jordan VC.

Eur J Cancer. 2009 Sep;45(13):2274-83. doi: 10.1016/j.ejca.2009.05.032. Epub 2009 Jul 9. Review.

PMID:
19592233
7.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
8.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

PMID:
21906462
9.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

PMID:
19118028
10.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y.

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228. Review.

PMID:
21342038
11.

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.

PMID:
19574470
12.

Pharmacogenetics of anti-estrogen treatment of breast cancer.

Del Re M, Michelucci A, Simi P, Danesi R.

Cancer Treat Rev. 2012 Aug;38(5):442-50. doi: 10.1016/j.ctrv.2011.08.003. Epub 2011 Sep 13. Review.

PMID:
21917382
13.

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

Stearns V, Rae JM.

Expert Rev Mol Med. 2008 Nov 20;10:e34. doi: 10.1017/S1462399408000896. Review.

PMID:
19019258
14.

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Goetz MP, Kamal A, Ames MM.

Clin Pharmacol Ther. 2008 Jan;83(1):160-6. Epub 2007 Sep 19. Review.

PMID:
17882159
15.

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.

Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X.

Cancer Chemother Pharmacol. 2013 Aug;72(2):287-303. doi: 10.1007/s00280-013-2195-9. Epub 2013 May 28. Review.

PMID:
23712329
16.
17.

Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.

Desmarais JE, Looper KJ.

J Clin Psychiatry. 2009 Dec;70(12):1688-97. doi: 10.4088/JCP.08r04856blu. Review.

PMID:
20141708
18.

Pharmacogenetics of endocrine therapy for breast cancer.

Higgins MJ, Stearns V.

Annu Rev Med. 2011;62:281-93. doi: 10.1146/annurev-med-070909-182545. Review.

PMID:
21226615
19.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

PMID:
24098545
20.

Hot flashes and their management in breast cancer.

Carpenter JS.

Semin Oncol Nurs. 2000 Aug;16(3):214-25. Review.

PMID:
10967794
Items per page

Supplemental Content

Write to the Help Desk